| Occurrence of COVID‐19 in priority groups receiving ChAdOx1 nCoV‐19 coronavirus vaccine (recombinant): a preliminary analysis from north India U Kaur, S Bala, B Ojha, S Jaiswal, S Kansal, SS Chakrabarti Journal of medical virology 94 (1), 407-412, 2022 | 30 | 2022 |
| Persistent health issues, adverse events, and effectiveness of vaccines during the second wave of COVID-19: a cohort study from a tertiary hospital in North India U Kaur, S Bala, A Joshi, NTS Reddy, C Japur, M Chauhan, N Pedapanga, ... Vaccines 10 (7), 1153, 2022 | 14 | 2022 |
| Identifying the mechanisms of α-synuclein-mediated cytotoxicity in Parkinson’s disease: new insights from a bioinformatics-based approach SS Chakrabarti, VS Sunder, U Kaur, S Bala, P Sharma, M Kiran, ... Future Neurology 15 (3), FNL49, 2020 | 6 | 2020 |
| Determinants of COVID-19 Breakthrough Infections and Severity in ChAdOx1 nCoV-19–Vaccinated Priority Groups U Kaur, S Bala, B Ojha, BK Pathak, A Joshi, AK Yadav, A Singh, S Kansal, ... The American Journal of Tropical Medicine and Hygiene 107 (4), 850, 2022 | 4 | 2022 |
| Persistent health issues, adverse events, and effectiveness of vaccines during the second wave of COVID-19: a cohort study from a tertiary hospital in North India. Vaccines … U Kaur, S Bala, A Joshi, JC NTS R, M Chauhan s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | 4 | 2022 |
| Patterns and predictors of COVID-19 occurrence and severity in vaccinated priority groups U Kaur, S Bala, B Ojha, BK Pathak, A Joshi, AK Yadav, A Singh, S Kansal, ... | 2 | 2021 |
| Role of oxidative stress in the pathogenesis of metabolic syndrome SS Chakrabarti, L Saso, S Bala, S Saha, E Profumo, B Buttari, ... Metabolic Syndrome, 143-156, 2024 | | 2024 |
| Resveratrol: A Novel Drug for the Management of Neurodegenerative Disorders S Bala, A Misra, U Kaur, S Shubhra Traditional Medicine for Neuronal Health, 230, 2023 | | 2023 |
